Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | $27.00 → $2.00 | Outperform → In-line | Evercore ISI |
| 6/18/2024 | Buy → Hold | TD Cowen | |
| 6/18/2024 | $35.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
| 6/17/2024 | Buy → Neutral | Guggenheim | |
| 6/17/2024 | Buy → Neutral | BTIG Research | |
| 6/17/2024 | $41.00 → $3.00 | Outperform → Neutral | Wedbush |
| 3/25/2024 | $21.00 → $65.00 | Buy | Jefferies |
| 12/8/2023 | $35.00 | Equal Weight | Wells Fargo |
SC 13G/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)
SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)
SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)
4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)
4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)
4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)
Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously
TD Cowen downgraded Aerovate Therapeutics from Buy to Hold
Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027 Conference call scheduled for October 31, 2024, at 8:30 AM EDT VANCOUVER, British Columbia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AV
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027 Conference call scheduled for October 31, 2024, at 8:30 AM EDT VANCOUVER, British Columbia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AV
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacGrow as the company's exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse mer
WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH). The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy, safety and tolerability of three different doses of AV-101 compared to placebo. The primary endpoint for the Phase 2b portion of IMPAHCT is change in PVR compared with placebo. Results
425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)
10-Q - Aerovate Therapeutics, Inc. (0001798749) (Filer)
425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)
Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by
Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by
4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g